Menu Search
Equities

Renovaro Inc

2Q5:DEU

Renovaro Inc

Actions
  • Price (EUR)0.48
  • Today's Change0.031 / 6.90%
  • Shares traded0.00
  • 1 Year change-81.82%
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

  • Revenue in USD (TTM)0.00
  • Net income in USD-115.69m
  • Incorporated2011
  • Employees25.00
  • Location
    Renovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
  • Phone+1 (212) 763-0184
  • Fax+1 (845) 818-3588
  • Websitehttps://renovarobio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RENB:NAQ since
announced		Transaction
value
Gedi Cube BvDeal completed13 Feb 202413 Feb 2024Deal completed-85.10%--
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.